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Is the pharmaceutical 
industry improving with 
regard to access to 
essential medicines?
Despite progress in many countries, 
about a third of the world’s 
population does not have regular 
access to essential medicines.1 
The responsibility to resolve this 
problem lies with many, including 
the pharmaceutical industry. Since 
2008, the Access to Medicine Index 
(the Index) has ranked the 20 largest 
research-based pharma ceutical 
companies according to their eﬀ orts 
in making relevant products more 
available, aﬀ ordable, and accessible 
in developing countries.2,3
The 2012 Index ranking is based 
on companies’ commitments 
and actions to provide medicines, 
vaccines, and diagnostic tests in 
103 low-income and middle-income 
countries, focusing on 33 high-burden 
communicable, non-communicable, 
and neglected tropical diseases, 
as well as a range of maternal and 
neonatal disorders. Information 
received from companies is cross-
checked with other sources, and peer 
reviewed by experts. The ranking 
is based on 101 indicators in seven 
technical areas: organisation and 
management of access programmes; 
conduct of relationships with policy-
makers, competitors, customers, and 
the public; research and develop-
ment on relevant products; pricing 
policies and distribution; patent 
and licensing practices; capacity 
building in developing countries; and 
product donations and philanthropic 
activities. For each technical area 
four aspects are assessed: company 
commit ment, transparency, perfor-
mance, and innovation.4
To complement the relative 
rankings of the 20 companies in the 
biennial index, we did an assessment 
of absolute changes in company 
performance over time. We did two 
analyses: a crude assessment of 
change in overall company scores, 
and a more detailed analysis of 
changes in the individual indicators 
that could be reliably compared 
across timepoints and which showed 
the highest correlation with overall 
company scores. We also identiﬁ ed 
the six most representative indicators 
for research activities and used 
the underlying absolute ﬁ gures to 
assess progress in company ﬁ nancial 
investments, research partnerships, 
and the pipeline of relevant 
molecules.4 Details of the methods 
and full results of our study are 
available elsewhere.5
Of 101 indicators in the Index, ten 
fulﬁ lled all comparability criteria for 
the detailed longitudinal analysis, 
and six core-scored indicators with 
the highest correlation with overall 
scores were used for the detailed 
longitudinal analysis. We made 
several important observations. 
First, the crude analysis of all 
101 indicator scores showed that 
17 of 20 companies increased 
the overall score underlying their 
Index ranking between 2010 and 
2012 (appendix). Although many 
indicators cannot be compared 
fully, this ﬁ nding presents a ﬁ rst 
indication of change. Second, 
50 (42%) of 120 company scores 
for the six core indicators increased 
in value, whereas only two (2%) 
of 120 decreased. These changes 
represent a very strong signal on 
the direction of change in company 
behaviour. The size of this change 
is not easy to measure, but an 
observed 84% rise in the overall 
average of the six indicators from 
1·45 to 2·67 (scale 0–5) is the best 
available estimate. This diﬀ erence is 
not signiﬁ cant because of the wide 
variation between the companies, 
but all six underlying average scores 
are also rising (ﬁ gure). Finally, we 
found that all six average numbers 
underlying the research indicators 
are also increasing, with a median 
increase of 132% (range 49–348%), 
suggesting that companies have 
more than doubled their research and 
development activities in diseases 
covered by the Index.
These average values mask many 
diﬀ erences between technical areas 
and between companies. For example, 
the industry seems well advanced in 
the area of governance and donations, 
but has a long way to go in data 
exclusivity and patents. Diﬀ erences 
between companies are presented in 
the full report.5
The question remains whether an 
increase in Index scores shows real 
progress in company behaviour. 
Companies with clear strategies to 
increase their Index ranking will have 
strengthened both their activities 
and their reports. However, all Index 
indicators, and especially those 
selected for this study, were chosen 
for their robustness and potential 
for veriﬁ cation. We believe that 
progress in the Index scores for these 
indicators is likely to represent real 
progress.
We therefore conclude that 
many of the top-20 research-
based pharmaceutical companies 
are moving in the right direction 
in their commitments and ac-
tivities to promote access to 
essential medi cines in low-income 
and middle-income countries. This 
ﬁ rst longitudinal as sess ment adds a 
dynamic pers pective to the biennial 
Index ranking, and will be used as a 
baseline for future assessments.
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Figure: Changes in six core ATM indicators, 2010–12
R&D=research and development.
See Online for appendix
Correspondence
e140 www.thelancet.com/lancetgh   Vol 2   March 2014
This study was funded by the ATM Foundation, 
which receives most of its funding from the Bill and 
Melinda Gates Foundation, the UK Department for 
International Development, and the Government of 
the Netherlands. We declare that we have no 
conﬂ icts of interest.
*Hans V Hogerzeil, Jayasree K Iyer, 
Lisanne Urlings, Tara Prasad, 
Sara Brewer
hans.hogerzeil@bluewin.ch
Access to Medicine Foundation, Haarlem, 
Netherlands, and Department of Global Health, 
University of Groningen, Netherlands (HVH); and 
Access to Medicine Foundation, Haarlem, 
Netherlands (JKI, LU, TP, SB)
1 WHO. The World Medicines Situation. Geneva: 
World Health Organization, 2011. http://www.
who.int/medicines/areas/policy/world_
medicines_situation/en/ (accessed Oct 15, 2013).
2 Hogerzeil HV. Big Pharma and Social 
Responsibility—the Access to Medicine Index. 
New Eng J Med 2013; 369: 896–99.
3 The Access to Medicine Index 2012. Haarlem, 
The Netherlands: Access to Medicine 
Foundation, 2012. http://www.
accesstomedicineindex.org/ranking (accessed 
Oct 16, 2013).
4 Access to Medicine Foundation. Methodology 
Report 2012. Haarlem, The Netherlands: 
Access to Medicines Foundation, 2012. http://
www.accesstomedicineindex.org/index-
publications (accessed Oct 16, 2013).
5 Longitudinal Analysis of the Access to 
Medicine Index. Haarlem, The Netherlands: 
Access to Medicine Foundation, 2013. http://
www.accesstomedicineindex.org/index-
publications (accessed Oct 16, 2013).
